Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus
— Clinical Proof-of-Concept Data Expected in Fourth Quarter of 2019 — CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 16, 2019-- Dicerna Pharmaceuticals, Inc . (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today...
View HTML
Toggle Summary Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update
— Initiated Screening of Participants to Enroll in the PHYOX™2 Phase 2 Pivotal Trial of DCR-PHXC for the Treatment of Primary Hyperoxaluria (PH) and Announced Updated Data from Ongoing PHYOX1 Phase 1 of DCR-PHXC – — Dosed First Healthy Volunteer in Phase 1 Clinical Trial of DCR-HBVS for Treatment...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the...
View HTML
Toggle Summary Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2019 financial...
View HTML
Toggle Summary Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX™2 Pivotal Trial
– Update Reflects Alignment with FDA on Path to Full Approval for Treatment of PH1 and Discussions Now Focusing on Appropriate Endpoints for PH2 and PH3 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2019-- Dicerna™ Pharmaceuticals, Inc.  (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive...
View HTML
Toggle Summary Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
—PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of Pediatric Nephrology 50 th Annual Meeting— —Company Announces Initiation of Participant Screening for PHYOX2 Pivotal Trial in PH1 and PH2— CAMBRIDGE, Mass....
View HTML
Toggle Summary Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
— 2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-On Offering — — Company’s Robust Cash Position Provides Funds Beyond 2020 to Fuel Pipeline Advancement and Growth — —...
View HTML
Toggle Summary Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after...
View HTML